ABSTRACT BACKGROUND Treatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) remains a major
Several studies have demonstrated that angiographic and clinical outcomes of patients treated for DES-ISR are poorer than those found in patients with bare-metal stent (BMS) ISR (3) (4) (5) (6) (7) . Indeed, the therapy of choice for patients with DES-ISR remains unsettled (3, 4) . Data from controlled clinical trials suggest that repeat DES implantation constitutes an attractive therapeutic strategy in this setting (7) (8) (9) (10) . Alternatively, drug-eluting balloons (DEB) also provide excellent late angiographic and clinical outcomes in patients with either BMS-or DES-ISR (11) (12) (13) (14) (15) (16) (17) (18) . In these patients, DEB are superior to conventional balloon angioplasty and at least similar to firstgeneration DES (11) (12) (13) (14) (15) (16) (17) (18) .
Second-generation DES are safer and more effective than first-generation DES (19, 20) . In particular, recent studies have shown uniquely favorable longterm results in patients treated with everolimuseluting stents (EES) (19, 20) . The value of newer DES has also been demonstrated in complex lesion subsets, including BMS-ISR and DES-ISR (21) . However, the relative efficacy of second-generation DES versus DEB in patients with DES-ISR remains unsettled.
METHODS

The RIBS IV (Restenosis Intra-Stent of Drug-Eluting
Stents: Drug-Eluting Balloon vs Everolimus-Eluting Stent) study is a prospective multicenter, open-label, controlled, randomized clinical trial comparing DEB and EES in patients with DES-ISR (Online Appendix).
The study protocol was published previously (22) . Inclusion and exclusion criteria were similar to those of previous RIBS trials (7, 8, 18, 21) . Eligible patients presented with angina or objective evidence of ischemia and showed DES-ISR on angiography (>50% diameter stenosis on visual assessment). Any type of DES presenting ISR was eligible, but patients in whom stent type could not be identified and those with unclear stent location were excluded. Patients with small vessels (#2.0 mm in diameter), very long lesions (>30 mm in length), or total occlusions (Thrombolysis In Myocardial Infarction ¼ 0) were also excluded (7, 8, 18, 21) . To avoid the possibility of including patients with stent thrombosis, patients with very early contraindications to aspirin or clopidogrel also were not eligible (7, 8, 18, 21) . Written informed consent was obtained from all patients.
Twenty-three university hospitals in Spain participated in this trial (Online Appendix). Telephonebased randomization was performed at the coordinating center (Clínico San Carlos, University Hospital, Madrid) using a computer-generated code.
Randomization (1:1) was stratified according to ISR length (#10 mm or >10 mm) and lesion location (intrastent-vs. edge-ISR) (22) . Clinical and angiographic outcome assessors were masked to the allocated treatment strategy; patients and treating physicians were not.
Data monitoring, collection, management, and analysis were organized by the coordinating center (22) . Vascular to support this study. These companies, however, played no role in the design of the study, data analysis, data interpretation, writing of the report, or the decision to submit it for publication. Dr. Moreno has received lecture fees from Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. INTERVENTIONS. Patients received pre-procedural aspirin and clopidogrel, with a loading dose (300 to 600 mg) administered to clopidogrel-naive patients.
Unfractionated heparin was used during the procedure with an initial bolus of 100 mg/kg, followed by additional boluses as necessary, to maintain an activated clotting time >250 s. The protocol mandated careful lesion pre-dilation. Initially, lesions were dilated with relatively short balloons at low pressures to avoid damage to the adjacent coronary segment.
Then high pressures were systematically recommended. If underexpanded stents were identified, the use of short noncompliant balloons at very high pressures was recommended (22) . Once adequate lesion pre-dilation was obtained, patients received the allocated treatment, with special attention paid to prevent "geographic miss" phenomena. In patients allocated to DEB (SeQuent Please, B. Braun Surgical, Melsungen, Germany), a 1.1:1 balloon-to-artery ratio was selected using nominal pressures (12 to 14 atm) for 60 s. Crossover to bailout stenting was strongly discouraged in this arm. However, crossover was allowed in cases of dilation failure (>50% residual diameter stenosis) or major (>type C) residual dis- FOLLOW-UP. Patients were followed at 6 to 9 months and 1 year; they will be followed annually for 5 years.
Late angiographic follow-up was scheduled at 6 to 9 months, but coronary angiography was performed earlier in patients with recurrent symptoms. Electronic case report forms were completed by the local investigators, monitored, and submitted to the coordinating center, where data were critically reviewed for consistency. Missing data requests and specific queries were sent to sites when necessary. The validated dataset was entered into a dedicated relational database used in all previous RIBS studies (7, 8, 18, 21) . ANGIOGRAPHIC ANALYSIS. All angiograms were analyzed at the central core laboratory by trained and blinded personnel using standard methodology (7, 8, 18, 21) . Lesion morphology was assessed using the Mehran (24) and American College of Cardiology/ American Heart Association (25) angiographic Results of EES in patients with DES-ISR were not available when the trial was designed so sample size calculation required major assumptions. Again, based on the previous RIBS studies, we assumed an MLD of 2.6 AE 0.4 mm immediately after stent implantation (7, 8) . In patients with BMS-ISR treated with sirolimus-eluting stents (SES), the RIBS II study showed a late loss of 0.13 mm (8), whereas the ISAR-DESIRE 1 study showed a late loss of 0.32 mm (9) .
However, in patients with DES-ISR, the ISAR-DESIRE 2 trial reported larger late loss (0.4 mm) using firstgeneration DES (10) . Assuming a worst-case scenario, a late loss of 0.6 mm after EES was assumed for the current study. Accordingly, an MLD of 2.0 AE 0.6 mm at follow-up was estimated in the EES arm (22) . Continuous data are presented as mean AE SD or median and interquartile range, as required, and were compared using the Student t test or Mann-Whitney test. Main effect estimates are presented with their 95% CI. Event-free survival was estimated from Kaplan-Meier curves and compared with the log-rank and Breslow exact tests. Hazard ratios and 95% confidence intervals were assessed using Cox models and compared with the Wald test. Results of main outcome measure were examined according to 10 prespecified, relevant clinical and angiographic variables previously detailed in other RIBS trials (7, 8, 18, 21) .
Interactions were tested by 2-way analysis of variance. Analyses were performed according to the intention-to-treat principle, unless otherwise specified. SPSS Statistics version 15.0 (SPSS Inc., Chicago, Illinois) was used. A p value <0.05 was considered statistically significant.
Authors from the coordinating center (F.A., M.J.P-V., A.C., C.F.) had full access to the study's entire dataset, performed the statistical analysis, and decided to submit the study for publication and take full responsibility in this regard. Statistical analyses 
were performed at the clinical epidemiology department at the coordinating center. (Table 2) . Importantly, based on in-lesion analysis, all major late angiographic findings (including binary restenosis rate and late loss) were significantly better in the EES arm ( Table 2) .
RESULTS
From
One-year clinical follow-up was obtained in all 309 patients (100%). Clinical events during the first year are summarized in Table 3 . During this time, analysis. This is relevant because the classic angiographic dictum "the more you gain, the more you lose" (29) was not observed in the present study, likely a result of the unique antiproliferative efficacy of EES. Therefore, EES not only led to larger acute angiographic gain but also showed less late loss at follow-up. Additionally, our findings were consistent for 10 pre-specified subgroups, emphasizing that the relative efficacy of EES compared with DEB was maintained in diverse clinical and angiographic scenarios. In patients with BMS-ISR, the RIBS II study (8) demonstrated the superiority of SES compared with balloon angioplasty, whereas the ISAR-DESIRE 1 study (9) demonstrated that both SES and paclitaxel-based In terms of absolute mean difference (AMD) in MLD, EES were superior to DEB overall, and all interactions within 10 pre-specified subgroups were not significant. p Values indicate the difference between strategies. B/A ¼ balloon-to-artery ratio; LAD ¼ left anterior descending coronary artery; RE ¼ restenosis; UA ¼ unstable angina; other abbreviations as in Figures 1 and 2 . Abbreviations as in Figure 1 .
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Everolimus-eluting stents provide greater freedom from in-stent restenosis and late target lesion revascularization than drug-eluting balloon angioplasty in patients with in-stent restenosis of coronary drugeluting stents during near-term follow-up.
TRANSLATIONAL OUTLOOK: Longer-term studies are needed to establish the optimum device type for percutaneous coronary revascularization in patients who develop in-stent restenosis of coronary drug-eluting stents.
